Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.47 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.47 |
| ▸ | GRIA1 | P42261 | 6/20 | 0.46 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.42 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.42 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.42 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.41 |
| ▸ | CHRND | Q07001 | 6/20 | 0.40 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.40 |
| ▸ | CHRNG | P07510 | 2/20 | 0.40 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.40 |
| ▸ | TLR2 | O60603 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9167972 | 1.00 | SIRT6 (0.47) | SIRT6SIRT1GRIA1GNAI3GNAO1 | |
| SCHEMBL7619519 | 1.00 | SIRT6 (0.47) | SIRT6SIRT1GRIA1GNAI3GNAO1 | |
| SCHEMBL929126 | 1.00 | SIRT6 (0.47) | SIRT6SIRT1GRIA1GNAI3GNAO1 | |
| Hydrochloric Acid SCHEMBL9472559 | 0.99 | SIRT6 (0.46) | SIRT6SIRT1GRIA1GNAI3GNAO1 | |
| Hydrochloric Acid SCHEMBL27630023 | 0.99 | SIRT6 (0.46) | SIRT6SIRT1GRIA1GNAI3GNAO1 | |
| Hydrochloric Acid SCHEMBL7621165 | 0.99 | SIRT6 (0.46) | SIRT6SIRT1GRIA1GNAI3GNAO1 | |
| Hydrochloric Acid SCHEMBL27630114 | 0.99 | SIRT6 (0.46) | SIRT6SIRT1GRIA1GNAI3GNAO1 | |
| SCHEMBL9164359 | 0.99 | SIRT6 (0.45) | SIRT6SIRT1GRIA1GNAI3GNAO1 | |
| SCHEMBL930922 | 0.99 | SIRT6 (0.45) | SIRT6SIRT1GRIA1GNAI3GNAO1 | |
| Hydrochloric Acid SCHEMBL9472254 | 0.97 | SIRT6 (0.44) | SIRT6SIRT1GRIA1GNAI3GNAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875268-B2 | The use of certain dimercaptoamides as reducing agents, 2-mercapto-N-(2-mercaptoethyl)acetamide, results in curling that is satisfactoryin terms of intensity and in terms of hold over time; less substantial degradation of the hair fiber compared with the reducing agents of the prior art; permanent waves | L'OREAL S.A. (FR) | 2011-01-25 | — | — | US | claimed |
| EP-1584615-B1 | Use of dimercaptoamides for permanently deforming of keratinic fibres | OREAL (FR) | 2008-05-28 | — | — | EP | claimed |
| US-20060013784-A1 | Novel dimercaptoamides, compositions comprising them as reducing agents, and processes for permanently reshaping keratin fibers therewith | L'OREAL S.A. (FR) | 2006-01-19 | — | — | US | claimed |
| EP-1584615-A1 | Use of dimercaptoamides for permanently deforming of keratinic fibres | L'OREAL (FR) | 2005-10-12 | — | — | EP | claimed |
| US-7875268-B2 | The use of certain dimercaptoamides as reducing agents, 2-mercapto-N-(2-mercaptoethyl)acetamide, results in curling that is satisfactoryin terms of intensity and in terms of hold over time; less substantial degradation of the hair fiber compared with the reducing agents of the prior art; permanent waves | L'OREAL S.A. (FR) | 2011-01-25 | — | — | US | disclosed |
| EP-1584615-B1 | Use of dimercaptoamides for permanently deforming of keratinic fibres | OREAL (FR) | 2008-05-28 | — | — | EP | disclosed |
| US-20060013784-A1 | Novel dimercaptoamides, compositions comprising them as reducing agents, and processes for permanently reshaping keratin fibers therewith | L'OREAL S.A. (FR) | 2006-01-19 | — | — | US | disclosed |
| EP-1584615-A1 | Use of dimercaptoamides for permanently deforming of keratinic fibres | L'OREAL (FR) | 2005-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060013784-A1 | Novel dimercaptoamides, compositions comprising them as reducing agents, and processes for permanently reshaping keratin fibers therewith | KRT18, CKAP4, S100A4 | SIRT6 1272/4885SIRT1 1208/4885GRIA1 4366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.